GlassScriptPhysician profile
Bryson Stair
NPI 1245596238
$1,475.88
in general payments reported to CMS, 2019-2025
18 companies · $638 in 2025
The $638 reported for 2025 was more than what 81% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.17 · 2022: $204 · 2023: $326 · 2024: $229 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $411.97 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $192.25 | 2021-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $192.19 | 2022-2025 | |
| Pulmonx Corporation | $102.89 | 2022-2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.18 | 2021-2023 | Spiriva Respimat |
| Grifols USA, LLC | $73.94 | 2021-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $67.47 | 2023 | Dupixent |
| Amgen INC. | $49.33 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $48.12 | 2025 | Yupelri |
| Mylan Specialty L.P. | $46.23 | 2022-2023 | Yupelri |
| Ethicon INC. | $43.37 | 2023 | Monarch Platform |
| Takeda Pharmaceuticals U.S.A., INC. | $41.42 | 2025 | Glassia |
| Insmed, INC. | $30.42 | 2025 | Arikayce |
| Verona Pharma, INC. | $26.36 | 2025 | Ohtuvayre |
| Covis Pharma Gmbh | $20.95 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $19.67 | 2025 | Vest Therapy Und |
| Vifor Pharma, INC. | $17.81 | 2025 | Zemaira |
| La Jolla Pharmaceutical Company | $13.31 | 2024 | Giapreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryson Stair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.